ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Tineafin® Tabletten:Bailleul (Suisse) SA
Complete information for professionalsDDDÄnderungen anzeigenPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
PackagesRegistration ownerLast update of information 
D01BA02 - TerbinafineATC-DDD Version 2016. Source: WHO
D - Dermatologicals

Most of the drugs in this group are preparations for topical use. Some few preparations for systemic use with clear dermatological applications, e.g. griseofulvin (antimycotic), retinoids (for treatment of acne) and psoralens and retinoids (for treatment of psoriasis) are classified in this group.

Only oral preparations in ATC group D are given DDDs. Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease. Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.

D01 - Antifungals for Dermatological Use

This group comprises preparations for topical and systemic treatment of dermatological mycoses. Preparations with systemic antimycotic effect, see also J02A - Antimycotics for systemic use.
Topical preparations used especially in gynecological infections are classified in G01A - Antiinfectives and antiseptics, excl. combinations with corticosteroids or G01B - Antiinfectives/antiseptics in combination with corticosteroids. Preparations for local treatment of fungal infections in the mouth, see A01AB - Antiinfectives and antiseptics for local oral treatment.

D01B - Antifungals for Systemic Use

This group comprises preparations used in the systemic treatment of dermatological mycoses. See also J02A - Antimycotics for systemic use.

D01BA - Antifungals for Systemic Use
 

The DDDs for griseofulvin and terbinafine are based on the treatment of dermatophyte infections in skin, hair or nails.

D01BA02 - Terbinafine
DoseRoute of administrationNote
 O 
2024 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home